Prolor Biotech cleared by FDA for US Phase II HGH Trials

Prolor Biotech Inc (PBTH), the biopharma firm utilising a proprietary CTP technology to commercialise longer-acting, biologically improved versions of existing therapeutics, reported receiving FDA regulatory clearance recently for Phase II clinical trials of hGH-CTP, the Company